Head-to-head evidence
AZD8630 vs GSK5784283
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: TSLP · full Asthma pipeline
AZD8630
Developed by AstraZeneca and partners
NCT06529419 · Phase 2 · completed
The study randomized 537 participants across three AZD8630 dose groups and placebo, with participants, care providers, investigators, and outcome assessors quadruple-blinded. Its primary endpoint was a clinical exacerbation-related measure, but the primary comparison cannot yet be judged because results have not been reported.
GSK5784283
Developed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT07712393 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD8630's landscape · GSK5784283's landscape